Your browser doesn't support javascript.
loading
Metformin in Type 2 Diabetes: Evidence for its Beneficial Effects on Frailty and Sarcopenia.
Pyrgioti, Elisavet E; Karakousis, Nikolaos D; Georgakopoulos, Petros N; Papanas, Nikolaos.
Afiliação
  • Pyrgioti EE; Pharmacist, Private Practice, Athens, Greece.
  • Karakousis ND; Second Department of Internal Medicine, Diabetes Centre-Diabetic Foot Clinic, Democritus University of Thrace, Alexandroupolis, Greece.
  • Georgakopoulos PN; Primary Healthcare, Internal Medicine Department, Amarousion, Attica, Greece.
  • Papanas N; Second Department of Internal Medicine, Diabetes Centre-Diabetic Foot Clinic, Democritus University of Thrace, Alexandroupolis, Greece.
Curr Diabetes Rev ; 20(3): e270723219177, 2024.
Article em En | MEDLINE | ID: mdl-37497698
ABSTRACT
This narrative review aimed to discuss the potential interplay among frailty syndrome, sarcopenia and metformin in type 2 diabetes mellitus (T2DM). There is emerging evidence on the potential protective role of metformin on both frailty and sarcopenia. However, results are not always consistent. Thus, further research is needed to provide a definitive answer on any role of metformin in improving frailty and/or sarcopenia in T2DM.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Sarcopenia / Fragilidade / Metformina Limite: Aged / Humans Idioma: En Revista: Curr Diabetes Rev Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Sarcopenia / Fragilidade / Metformina Limite: Aged / Humans Idioma: En Revista: Curr Diabetes Rev Ano de publicação: 2024 Tipo de documento: Article